TrialBMC cancer2012

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

Andreas G Niethammer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.